Market revenue in 2023 | USD 4.2 million |
Market revenue in 2030 | USD 5.6 million |
Growth rate | 4.2% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Pharmacodynamics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.71% in 2023. Horizon Databook has segmented the South Africa cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
The South Africa cell and gene therapy bioanalytical testing services market is expected to grow significantly over the forecast period. The South African Medical Research Council (SAMRC) is the government agency responsible for funding gene and cell therapy research.
Competitive international grants from the European Union, the Global Fund, the National Institutes of Health, and the Bill and Melinda Gates Foundation, among others, are another source of funding. According to an article published by NCBI, in June 2022, South Africa does not have licensed gene therapy products.
Cost is, however, the biggest obstacle. Furthermore, strategic initiatives by market players contribute to market growth. For instance, On June 29, 2021, The American Society of Gene and Cell Therapy (ASGCT) collaborated with the South African Society of Hematology, the South African National Blood Service, the South African Society of Clinical Hematology, the South African Stem Cell Transplant Society, and the South African Bone Marrow Registry to organize a half-day conference. The presenters included both local and worldwide experts in monogenic illnesses, cell treatment, and regulatory concerns.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into South Africa cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account